Pharmacomodulation of 7-(2-methylene-butyryl)-2,3-dihydrobenzoxazin-[1,4]-3-one structure and normolipemic activity.
A series of compounds from 7-(2-methylene butyryl)-2,3-dihydro benzoxazin-[1,4]-3-one was synthesized and evaluated for its lipid lowering action in animal models. Substitutions in positions 2, 4 and 7 were performed. The results of the structure-activity relationships are very difficult to be interpreted. The different modifications tested did not show any improvement in the normolipemic activity.